Cargando…
Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma
Liver hepatocellular carcinoma (LIHC) is the most prevalent primary cancer of the liver, and immune-related genes (IRGs) regulate its development. So far, there is still no precise biomarker that predicts response to immunotherapy in LIHC. Therefore, this research seeks to identify immunogenic progn...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7542239/ https://www.ncbi.nlm.nih.gov/pubmed/33195412 http://dx.doi.org/10.3389/fmolb.2020.567950 |
_version_ | 1783591516190539776 |
---|---|
author | Wu, Lei Quan, Wen Luo, Qiong Pan, Ying Peng, Dongxu Zhang, Guihai |
author_facet | Wu, Lei Quan, Wen Luo, Qiong Pan, Ying Peng, Dongxu Zhang, Guihai |
author_sort | Wu, Lei |
collection | PubMed |
description | Liver hepatocellular carcinoma (LIHC) is the most prevalent primary cancer of the liver, and immune-related genes (IRGs) regulate its development. So far, there is still no precise biomarker that predicts response to immunotherapy in LIHC. Therefore, this research seeks to identify immunogenic prognostic biomarkers and explore potential predictors for the efficacy of anti-PD-1/PD-L1 therapies in LIHC. The clinical data and gene expression profiles of patients diagnosed with LIHC were downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Moreover, IRGs were obtained from the ImmPort database. We discovered 35 IRGs that were differentially expressed between LIHC tissues and corresponding normal tissues. Through univariate Cox regression analysis, eight prognostic differentially expressed IRGs (PDEIRGs) were identified. Further, three optimal PDEIRGs (BIRC5, LPA, and ROBO1) were identified and used to construct a prognostic risk signature of LIHC patients via multivariate Cox regression analysis. The signature was validated by ROC curves. Subsequently, based on gene set enrichment analysis (GSEA) analysis, two out of the three optimal PDEIRGs (BIRC5 and LPA) were significantly enriched in the mismatch repair (MMR) pathway. Moreover, the two PDEIRGs (BIRC5 and LPA) were significantly correlated with the expression of genes related to mismatch repair (MLH1, MSH2, MSH6, and PMS2). Furthermore, correlations between the two PDEIRGs (BIRC5 and LPA) and immune checkpoints of cancer treatment (such as CTLA4, PD-1, and PD-L1) were demonstrated. Hyperprogressive disease (HPD) is a novel pattern of tumor progression which has a close relationship with immune checkpoint inhibitors (ICIs) utilization. MDM2 family amplification might promote the HPD phenomenon. Finally, we found a positive regulatory relationship between HPD related gene (MDM2) and BIRC5. Notably, MDM2 can either interact directly with BIRC5 or indirectly via downstream transcription factors of BIRC5. Overall, our study uncovered a novel 3-immune-related prognostic genes in LIHC. |
format | Online Article Text |
id | pubmed-7542239 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75422392020-11-13 Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma Wu, Lei Quan, Wen Luo, Qiong Pan, Ying Peng, Dongxu Zhang, Guihai Front Mol Biosci Molecular Biosciences Liver hepatocellular carcinoma (LIHC) is the most prevalent primary cancer of the liver, and immune-related genes (IRGs) regulate its development. So far, there is still no precise biomarker that predicts response to immunotherapy in LIHC. Therefore, this research seeks to identify immunogenic prognostic biomarkers and explore potential predictors for the efficacy of anti-PD-1/PD-L1 therapies in LIHC. The clinical data and gene expression profiles of patients diagnosed with LIHC were downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Moreover, IRGs were obtained from the ImmPort database. We discovered 35 IRGs that were differentially expressed between LIHC tissues and corresponding normal tissues. Through univariate Cox regression analysis, eight prognostic differentially expressed IRGs (PDEIRGs) were identified. Further, three optimal PDEIRGs (BIRC5, LPA, and ROBO1) were identified and used to construct a prognostic risk signature of LIHC patients via multivariate Cox regression analysis. The signature was validated by ROC curves. Subsequently, based on gene set enrichment analysis (GSEA) analysis, two out of the three optimal PDEIRGs (BIRC5 and LPA) were significantly enriched in the mismatch repair (MMR) pathway. Moreover, the two PDEIRGs (BIRC5 and LPA) were significantly correlated with the expression of genes related to mismatch repair (MLH1, MSH2, MSH6, and PMS2). Furthermore, correlations between the two PDEIRGs (BIRC5 and LPA) and immune checkpoints of cancer treatment (such as CTLA4, PD-1, and PD-L1) were demonstrated. Hyperprogressive disease (HPD) is a novel pattern of tumor progression which has a close relationship with immune checkpoint inhibitors (ICIs) utilization. MDM2 family amplification might promote the HPD phenomenon. Finally, we found a positive regulatory relationship between HPD related gene (MDM2) and BIRC5. Notably, MDM2 can either interact directly with BIRC5 or indirectly via downstream transcription factors of BIRC5. Overall, our study uncovered a novel 3-immune-related prognostic genes in LIHC. Frontiers Media S.A. 2020-09-24 /pmc/articles/PMC7542239/ /pubmed/33195412 http://dx.doi.org/10.3389/fmolb.2020.567950 Text en Copyright © 2020 Wu, Quan, Luo, Pan, Peng and Zhang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Molecular Biosciences Wu, Lei Quan, Wen Luo, Qiong Pan, Ying Peng, Dongxu Zhang, Guihai Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma |
title | Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma |
title_full | Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma |
title_fullStr | Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma |
title_full_unstemmed | Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma |
title_short | Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma |
title_sort | identification of an immune-related prognostic predictor in hepatocellular carcinoma |
topic | Molecular Biosciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7542239/ https://www.ncbi.nlm.nih.gov/pubmed/33195412 http://dx.doi.org/10.3389/fmolb.2020.567950 |
work_keys_str_mv | AT wulei identificationofanimmunerelatedprognosticpredictorinhepatocellularcarcinoma AT quanwen identificationofanimmunerelatedprognosticpredictorinhepatocellularcarcinoma AT luoqiong identificationofanimmunerelatedprognosticpredictorinhepatocellularcarcinoma AT panying identificationofanimmunerelatedprognosticpredictorinhepatocellularcarcinoma AT pengdongxu identificationofanimmunerelatedprognosticpredictorinhepatocellularcarcinoma AT zhangguihai identificationofanimmunerelatedprognosticpredictorinhepatocellularcarcinoma |